Skip To Main Content
Barbara De Moerloose on Muck Rack

Barbara De Moerloose

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome

|
By Laura Moser, Martin Hutter, Anna Alonso-Saladrigues, Andishe Attarbaschi, Francis Ayuk, Claudia D. Baldus, Adriana Balduzzi, Halvard Bönig, Jean-Pierre Bourquin, Jochen Buechner, Veit L. Buecklein, Saskia Burridge, Friso G. Calkoen, Gunnar Cario, Barbara De Moerloose, Marie-Emilie Dourthe, Tobias Feuchtinger, Anna Füreder, Julia Hauer, Marianne Ifversen, Andrea Jarisch, Krzysztof Kalwak, Jan-Henning Klusmann, Guido Kobbe, Christian Koenecke, Annette Künkele, Roland Meisel, Pietro Merli, Monika Mielcarek-Siedziuk, Fabian Muller, Ingo Müller, Sara Napolitano, Macarena Oporto Espuelas, Olaf Penack, Florence Rabian, Claudia Rössig, Martin G. Sauer, Arend von Stackelberg, Brigitte Strahm, Semjon Willier, Peter Bader, Susana Rives, Nicolas Boissel, Franco Locatelli, Sara Ghorashian, Andre Baruchel, Martina Ahlmann, Gustavo de Oliveira Canedo, Paul G. Schlegel
| Nature Verified
Abstract This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure.
Open in Who Shared Issue with article?

Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency - Blood Cancer Journal

|
By Lili Kotmayer, Guolian Kang, Ayami Yoshimi, Rebecca Voss, Barbara De Moerloose, Henrik Hasle, Kirsi Jahnukainen, Riccardo Masetti, Jochen Buechner, Marek Ussowicz, Paula Kjöllerström, Dominik Turkiewicz, Markus Schmugge, Victoria Okhomina, Cristian Sotomayor, Claudia Wehr, Nathan Gray, Alessandra Giorgetti, Charlotte M. Niemeyer, Luca Vinci
| Nature Verified
Abstract GATA2 deficiency is an autosomal dominant transcriptopathy disorder with high risk for myelodysplastic syndrome (MDS). To elucidate genotype-phenotype associations and identify new genetic risk factors for MDS, we analyzed 218 individuals with germline heterozygous GATA2 variants. We observed striking age-dependent incidence patterns in GATA2-related MDS (GATA2-MDS), with MDS being absent in infants, rare before age 6 years, and steeply increasing in older children.
Open in Who Shared Issue with article?

Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations | Leukemia

|
By Frédéric Millot, Nirmalya Roy Moulik, Sanjay Tewari, Mahmoud A Hammad, Herbert Pichler, Haruko Shima, Wenyu Yang, Roula Farah, Barbara De Moerloose, Kirk R. Schultz, Krzysztof Kalwak, Nobuko Hijiya, Markus Metzler
| Nature Verified
Abstract The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs).
Open in Who Shared Issue with article?
See all 6 articles